SGP vs AVLN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SGP · SpyGlass Pharma$36.95 ▲ 8.41%
AVLN · Avalyn Pharma$29.15 ▲ 9.30%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SGP +61.1%
- AVLN -1.2%
Head to head
| Metric | SGP | AVLN |
|---|---|---|
| Price | $36.95 | $29.15 |
| Change today | ▲ 8.41% | ▲ 9.30% |
| Market cap | $1.24B | $1.29B |
| Return, 3 months | +46.8% | -15.7% |
| Return, year to date | – | – |
| Return, 1 year | – | – |
| P/E (TTM) | – | – |
| P/B | 5.3 | 3.2 |
| P/E percentile vs own 5y | 25th | 89th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -129.0% | -43.3% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -24.1% | -25.9% |
| Analyst target vs. price | +6.5% | +93.2% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 80 | 60 |
| 30-day volatility | 56.3% | 63.5% |
| Max drawdown, 1 year | -40.8% | -40.6% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AVLN is the largest of the group by market value.
- SGP has been the calmest stock over the last 30 days.